ThirdLaw Molecular, a Blue Bell-based Temple University spinout, was featured by The Philadelphia Business Journal for “advancing a new technology it believes can be used to design and create more effective drugs faster and cheaper than those currently available.” Dr. Christian Schafmeister, ThirdLaw’s founder and president, is creating a “revolutionary” category of molecules via the company’s Spiroligomer technology.